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Abstract: Allergen-specific immunotherapy with house dust mite (HDM) aller-
gen extracts can effectively alleviate the symptoms of allergic rhinitis and as-
thma. The efficacy of the immunotherapeutic treatment is highly dependent on 
the quality of house dust mite vaccines. This study was performed to assess the 
stability of house dust mite allergen vaccines prepared for sublingual immuno-
therapy. Lyophilized Dermatophagoides pteronyssinus (Dpt) mite bodies were 
the starting material for the production of sublingual vaccines in four thera-
peutic concentrations. The stability of the extract for vaccine production, which 
was stored below 4 °C for one month, showed consistence in the protein profile 
in SDS PAGE. ELISA-inhibition showed that the potencies of Dpt vaccines 
during a 12 month period were to 65–80 % preserved at all analyzed therapeu-
tic concentrations. This study showed that glycerinated Dpt vaccines stored at 4 °C 
preserved their IgE-binding potential during a 12 month period, implying their 
suitability for sublingual immunotherapeutic treatment of HDM allergy. 
Keywords: Dermatophagoides pteronyssinus; allergen extract; vaccines; ELISA 
inhibition; stability. 
INTRODUCTION 
The protein allergens of house dust mite Dermatophagoides pteronyssinus 
can cause severe allergic disease in susceptible individuals.1 Allergen extract pre-
pared from cultured dust mites has been used for diagnosis as well as for sub-
lingual-swallow immunotherapy. The beneficial effect of immunotherapy (IT) 
with crude extract or partly purified allergen had been demonstrated in certain 
IgE-mediated disorders, such as seasonal allergic rhinitis and asthma.2,3 
Allergen stability, i.e., persistence of adequate quantities of relevant antigens 
in an allergen vaccine from the time of initial assay to the time of clinical use, is 
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enhanced by addition of glycerol to the vaccine solution.4,5 Mite extracts contain 
at least 20 well-characterized allergens. Several of these proteins appear to be 
highly immunoreactive in humans with evidence of specific IgE to the individual 
allergens in up to 80 % of individuals allergic to mites.5 Four of these allergen 
groups (1, 3, 6 and 9) are proteolytic enzymes and, due to their biological acti-
vity, may compromise the stability of extracts. Several investigators evaluated 
the stability of mite allergens in commercially available vaccine preparations.4,6–9 
Due to the presence of proteolytic enzymes, glycerol has been considered as a 
stabilizing agent in house dust mite allergen extracts,10 since protease inhibitors 
did not contribute to the stability of a mite extract.11 However, in addition to 
optimization of the procedure for the preparation of a potent allergen vaccine, 
evaluation of its stability from the time of preparation to the intended clinical use 
is of major importance for reliable and effective immunotherapeutic treatment. 
The aim of this work was to investigate the relative potency of a mite sub-
lingual-swallow immunotherapeutic vaccine stabilized with 50 % glycerol, stored 
at 4 °C (producer recommendation) over a 12-month period. The stability of a 
pure mite extract was also examined over a 1-month storage period at the same 
temperature as used for the preparation of vaccines. 
EXPERIMENTAL 
Allergen extract preparation  
The house dust mite extract was prepared from dried house dust mite bodies of Derma-
tophagoides pteronyssinus. The certificate of analysis for the starting material declared 95 % 
purity and 5 % medium particles. The extraction procedure was realized according to the 
manufacturer’s recommendation.12 In brief, the extraction was performed overnight at 4–8 °C 
using a 1 % solution in 0.15 M phosphate-buffered saline (PBS) pH 7.6. The extract was 
clarified by centrifugation at 2000 rpm for 30 min and subsequently filtered through a 0.22 
μm membrane disc filter (Pall Europe Limited, Portsmouth, UK). The protein content was 
quantified according to the Kjeldal method.13 
Allergen vaccines preparation 
The D. pteronyssinus protein extract was used for the preparation of sublingual-swallow 
vaccines in PBS with 50 % glycerol. The vaccine marked as “3”, with a concentration of 1000 
PNU (protein nitrogen units), was used for the preparation of three serial dilutions designated 
as “2”, “1”, and “0”, containing 125, 16 and 2 PNU, respectively. All vaccines were stored at 
4 °C during the investigation period. 
Human sera 
The sera from 10 patients allergic to house dust mites with a documented clinical history 
of HDM allergy and without a record on immunotherapy to this allergen were used for the 
serological analysis.  
SDS PAGE and Western blot  
SDS PAGE was performed according to Laemmli.14 The gel was either stained with 
Coomassie Brilliant Blue R-250 (CBB) to visualize the separated proteins or the resolved 
components were blotted by a semi-dry electrotransfer onto a nitrocellulose membrane (0.45 
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μm, Serva, Heidelberg, Germany). The membrane was blocked in 20 mM Tris-buffered saline 
(TBS) containing 1 % BSA and 0.1 % Tween 20 for 1 h and dried until development. 
IgE detection 
IgE-reactive proteins were detected in Western blots with 5-fold diluted individual pa-
tient’s sera in TBS-buffer with 0.1 % BSA. Alkaline phosphatase labeled monoclonal anti-hu-
man IgE (1:1000, Sigma Chemical Co., St Louis MO, USA) was used as the secondary anti-
body. The binding patterns were visualized with a substrate solution of 1.5 mg BCIP (5-bro-
mo-4-chloro-3-indolyl phosphate, Serva, Heidelberg, Germany) and 3 mg NBT (nitro blue 
tetrazolium, Serva, Heidelberg, Germany) in 10 mL of 100 mM Tris buffer, containing 150 
mM NaCl and 5 mM MgCl2, pH 9.6, according to Harlow & Lane.15 
Evaluation of vaccine potency by ELISA-inhibition 
The potency of each of the four vaccines was investigated by ELISA-inhibition with a 
pool of the sera from the allergic persons. Vaccine sampling has been performed after zero, 
three and 12 months of storage, and the potency was titrated in 6 dilutions. Microtiter plates 
(Nunc-Immuno Plate, Maxisorp, Inter med, Denmark) were coated with 100 µl/well (10 
μg/mL protein concentration) of D. pteronyssinus extract in 0.06 M carbonate buffer, pH 9.6, 
overnight at 4 °C. The plate was washed with PBS containing 0.05% Tween 20 (PBS-T) and 
blocked with 0.1% bovine serum albumin dissolved in PBS-T (PBS-T-B) for 1 h at room tem-
perature. The subsequent steps were performed using PBS-T-B as diluent, and washings in 
PBS-T were realized between the following steps: the plate was incubated with 100 µl of the 
pool of patients’ sera (CAP class 1 to 6; diluted 1:5 in PBS-T-B) previously incubated with 
decreasing concentrations of the vaccine (diluted 1, 5, 10, 100, 500, 1000 and 5000 times) at 
37 °C for 2 h. Subsequently, the plate was incubated with 100 µl of anti-human IgE (Sigma) 
for 2 h at room temperature. The assay was developed by adding 100 µl of the enzyme sub-
strate (pNPP 1 mg/mL in 0.1 M diethanolamine buffer, pH 9.6), and the absorbance was 
measured at 405 nm using a plate reader (Multiskan) after 60 min of incubation. A serum 
from a non-allergic person was used as the negative control. 
RESULTS AND DISCUSSION 
SDS PAGE 
Coommasie Brilliant Blue staining of a one-dimensional SDS PAA gel re-
vealed a complex protein pattern for the Dpt extract in the range of about 12–116 
kD (Fig. 1). The dominant protein bands were at about 116 kD, 25–30 kD, and 
12–18 kD. SDS-PAGE analysis of pure non-glycerinated Dpt extract was em-
ployed for the evaluation of the extract quality, expressed through the protein 
bands detected after one month of storage. Under the employed experimental 
conditions, storage of the Dpt extract at 4 °C was suitable as the starting material 
for vaccine production. A longer period of storage (two months) revealed deterio-
ration of the protein extract, suggesting one-month period at 4 °C as the maxi-
mum for an extract intended for vaccine preparation. 
IgE binding profile of separated mite components 
Immunoblots were performed using the sera of allergic patients with specific 
IgE class 6, and class 3 (Fig. 2). These immunoblots showed that patients’ sera 
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class 6 recognized most of the proteins present in the extract while patients’ sera 
class 3 recognized proteins of about 14 and 25 kD (major allergens) and some of 
higher molecular mass. 
Fig. 1. Separation of house dust mite whole-body extracts by SDS gel 
electrophoresis on a 12 % PA gel: mm – molecular mass markers, 1m – 1st 
month. 
Fig. 2. IgE reactivity of the HDM extract with 
patients’ sera class 6 and class 3, mm – mole-
cular mass markers, Ex – extract. 
ELISA-inhibition 
Dpt vaccine “0” and “1” showed 100 % inhibition in full concentration after 
zero and after three months; however, the potency was reduced to 66 %, and 75 %, 
respectively after 12 months (Figs. 3 and 4). A remarkable decrease in potency of 
both vaccines was noticed within the first dilution and continued throughout the 
investigated period. The decrease could be ascribed not only to dilution of the 
glycerol as the stabilizing agent of the allergen proteins, but also to protein insta-
bility in diluted concentrations (2, and 16 PNU). Vaccines “2” and “3” showed 
100 % inhibition after zero and after three months period. The high IgE inhibition 
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potential of these vaccines (> 80 %) was preserved after 12 months (Figs. 5 and 
6). Vaccine “3”, with the highest allergen concentration, retained high IgE inhibi-
tion potential at almost all dilutions after 12 months storage. 
Fig. 3. IgE ELISA-inhibition 
of vaccine SLIT “0” during 12 
months: percentage of in-
hibition vs. logarithm of dilu-
tion, (diln – volumetric ratio 
of solution and diluent). 
Fig. 4. IgE ELISA-inhibition 
of vaccine SLIT “1” during 12 
months: percentage of in-
hibition vs. logarithm of dilu-
tion, (diln – volumetric ratio 
of solution and diluent). 
Fig. 5. IgE ELISA-inhibition 
of vaccine SLIT “2“ during 12 
months: percentage of inhibi-
tion vs. logarithm of dilution, 
(diln – volumetric ratio of so-
lution and diluent). 
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Fig. 6. IgE ELISA-inhibition 
of vaccine SLIT “3” during 12 
months: percentage of inhibi-
tion vs. logarithm of dilution, 
(diln – volumetric ratio of so-
lution and diluent). 
The stability of allergen extracts expressed as IgE inhibition potential de-
pends on many factors, including the starting material, the method of manufac-
ture, dilution, stored temperature, etc. It was already noticed that the loss of po-
tency was higher in diluted allergen extracts and at higher storage temperatu-
res.16 Nelson et al. explained the loss of potency in dilute extracts by adsorption 
of protein onto the surface of the vial, which could be decreased by the addition 
of extra protein, such as human serum albumin, to the extract.17 Thereafter, the 
presence of proteases in some allergen extracts, which could break down aller-
genic proteins, was recognized as an additional cause for the loss of potency. The 
presence of proteases was confirmed in allergen extracts of fungi,18 cockroaches 
and house dust mite.19,20 
Allergen manufacturers usually recommend storage of commercial allergen 
vaccines at 4 °C for a 12-month period.12 Guided by this recommendation, the 
stability of Dpt allergen vaccine intended for application in sublingual-swallow 
immunotherapy was investigated. Four therapeutic concentrations were analyzed: 
solution “3”, with the highest concentration (1000 PNU), was used for the prepa-
ration of serial vaccine dilutions in the proportion 1:7. Solution “3” showed the 
highest stability maintained over 12 months, expressed as more than 80 % pre-
served inhibition potential. The other solutions also retained a high % of inhi-
bition (more than 65 %) during the investigated period. Glycerol used in the vac-
cine preparation seems to be a good stabilizer for D. pteronyssinus allergens. A 
protective effect was reported for 25 % glycerol, while 50 % glycerol, which was 
also found to be effective in the present study, was described as being able to 
inhibit enzyme activity.16 
CONCLUSIONS 
This study showed that allergen vaccines intended for sublingual HDM im-
munotherapy fulfill the requirement for the estimated potency, derived from an 
assay of total allergenic activity to be not less than 50 % of the stated potency,21 
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by retaining more than 65 % of inhibition after 12 months storage at 4 °C. All re-
levant Dpt allergens were presented in the primary house dust mite extract which 
was used for the preparation of the vaccines. However, the rapid advancement in 
recombinant DNA technology, peptide synthesis and protein analysis will offer 
new opportunities for the design and improvements in the standardization of al-
lergen vaccines in the near future. 
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И З В О Д  
ИСПИТИВАЊЕ СТАБИЛНОСТИ ВАКЦИНЕ КУЋНЕ ПРАШИНЕ 
ЗА СУБЛИНГВАЛНУ ИМУНОТЕРАПИЈУ 
ЛИДИЈА БУРАЗЕР1, КАТАРИНА МИЛОВАНОВИЋ1, ТАЊА ЋИРКОВИЋ-ВЕЛИЧКОВИЋ2 
и МАРИЈА ГАВРОВИЋ-ЈАНКУЛОВИЋ2 
1Institut za virusologiju, vakcine i serume Torlak, Beograd i 
2Hemijski fakultet, Univerzitet u Beogradu, Beograd 
Алерген-специфична имунотерапија представља поступак који може да промени ток 
болести код алергијског ринитиса и астме. Квалитет вакцине припремљене од кућних гриња 
значајно утиче на ефикасност имунотерапеутског третмана. Испитивање је имало за циљ 
процену стабилности вакцине кућних гриња намењене за сублингвалну имунотерапију. Тело 
лиофилозованих Dermatophagoides pteronyssinus гриња (Dpt-гриња) употребљено је као по-
лазни материјал за производњу сублингвалне вакцине у 4 различита терапеутска разбла-
жења. Потентност Dpt вакцина праћена ELISA-инхибицијом у 4 терапеутска разблажења, 
након 12 месеци задржан је у свим разблажењима у опсегу 65–80 %. Испитивање је показало 
да глицеролом стабилизоване Dpt вакцине за сублигвалну имунотерапију, уз чување на 4 °C 
задржавају алергени потенцијал (> 65 %) након 12 месеци од њихове припреме, и као такве 
могу се користити за третман алергије на кућне гриње. 
(Примљено 30. априла, ревидирано 7. јула 2009) 
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